Prostate Cell News Volume 6.01 | Jan 16 2015

    0
    23
    Prostate Cell News 6.01 January 16, 2015

    Prostate Cell News

         In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  PCN on Twitter

     
    TOP STORY
    Transfected Poly(I:C) Activates Different dsRNA Receptors Leading to Apoptosis or Immunoadjuvant Response in Androgen-Independent Prostate Cancer Cells
    Researchers characterized the receptors and the signalling pathways involved in the remarkable apoptosis induced by poly(I:C) transfected by lipofectamine compared to twelve-fold higher free poly(I:C) concentration in PC3 and DU145 cells. [J Biol Chem] Abstract | Full Article
    New TeSRâ„¢-E8â„¢ is Here For Feeder-Free Culture of Human ES Cells and iPS Cells

     
    PUBLICATIONS (Ranked by impact factor of the journal)
    LABORATORY RESEARCH

    LEF1 Targeting EMT in Prostate Cancer Invasion Is Regulated by miR-34a
    Investigators describe the molecular mechanism of microRNA-34a (miR-34a) and lymphoid enhancer-binding factor-1 (LEF1) in cooperatively regulating prostate cancer cell invasion. [Mol Cancer Res] Abstract

    Hepsin Inhibits CDK11p58 I.E. Activity by Suppressing Unr Expression and eIF-2α Phosphorylation in Prostate Cancer
    Scientists found that hepsin inhibited the internal ribosome entry site activity and expression of CDK11p58, which is associated with cell cycle progression and pro-apoptotic signaling in prostate cancer. [Cell Signal] Abstract

    FOXO3a Modulates WNT/β-Catenin Signaling and Suppresses Epithelial-to-Mesenchymal Transition in Prostate Cancer Cells
    Researchers demonstrate that forkhead box-O (FOXO)3a significantly inhibits the expression β-catenin in prostate cancer cells. The mechanism of inhibiting β-catenin expression involves the FOXO3a-mediated transactivated microRNA-34b/c, which consequently suppressed β-catenin mRNA expression by targeting the untranslated regions of β-catenin. [Cell Signal] Abstract

    The Potential of Neurotensin Secreted from Neuroendocrine Tumor Cells to Promote Gelsolin-Mediated Invasiveness of Prostate Adenocarcinoma Cells
    Researchers investigated the interactions between neuroendocrine cells and LNCaP cells and the involvement of gelsolin in contributing to the invasive potential of LNCaP cells. [Lab Invest] Abstract

    NUSAP1 Expression Is Upregulated by Loss of RB1 in Prostate Cancer Cells
    NUSAP1 expression is elevated in the RB1-null DU145 prostate cancer cell line, as opposed to LNCaP and PC-3 cell lines. Furthermore, NUSAP1 expression increases upon knockdown of RB1 in prostate cancer cell lines and decreases after knockdown of E2F1. [Prostate] Abstract

    CYP3A5 Regulates Prostate Cancer Cell Growth by Facilitating Nuclear Translocation of AR
    Scientists elucidated the mechanism of regulation of androgen receptor (AR) expression by CYP3A5. CYP3A5 siRNA blocked growth of LNCaP and C4-2 cells by 30-60%. [Prostate] Abstract

    Adiponectin Inhibits VEGF-A in Prostate Cancer Cells
    Prostate cancer cell lines examined had all lower levels of adiponectin and adiponectin receptor I, compared to normal healthy prostate tissue. Moreover, overexpression of adiponectin in prostate cancer cells decreased production of vascular endothelial growth factor A (VEGF-A), while adiponectin depletion increased VEGF-A. [Tumor Biol] Abstract

    Oxidized Low-Density Lipoprotein Is Associated with Advanced-Stage Prostate Cancer
    Scientists investigated the function of oxidized low-density lipoprotein (ox-LDL) in prostate cancer cell lines in vitro. Phosphorylation protein chips were used to analyze cell signaling pathways in ox-LDL-treated PC-3 cells. [Tumor Biol] Abstract

    Inhibitory Action of Pristimerin on Hypoxia-Mediated Metastasis Involves Stem Cell Characteristics and EMT in PC-3 Prostate Cancer Cells
    The authors investigated whether pristimerin affects the bone metastasis, stem cell characteristics and epithelial-mesenchymal transition (EMT) of prostate cancer PC-3 cells subjected to hypoxia. [Oncol Rep] Abstract

    CLINICAL RESEARCH

    Radium-223 Dichloride: A Novel Treatment Option for Castration-Resistant Prostate Cancer Patients with Symptomatic Bone Metastases
    The authors reviewed and evaluated the clinical trial efficacy and safety of radium 223 along with its place in therapy in men with castration-resistant prostate cancer. [Ann Pharmacother] Abstract

    Mutation Detection in Formalin-Fixed Prostate Cancer Biopsies Taken at the Time of Diagnosis Using Next-Generation DNA Sequencing
    Scientists assessed whether next-generation DNA sequencing can be used to screen prostate cancer for multiple gene alterations in men routinely diagnosed with this disease and/or who are entered into clinical trials. [J Clin Pathol] Abstract

    Listen Now: Podcast on ALDH in Breast Cancer Treatment Response

     
    REVIEWS
    Immunotherapy for Castration-Resistant Prostate Cancer: Progress and New Paradigms
    The authors describe the rationale for immunotherapy for prostate cancer, summarize the approaches under evaluation, and discuss sequencing options for immunotherapy in the current treatment paradigm. [Urol Oncol] Full Article

    Visit our reviews page to see a complete list of reviews in the prostate cell research field.

     
    INDUSTRY NEWS
    Prostate Cancer Foundation Announces 6 New Challenge Awards for New Discoveries in Treatment Sciences
    The Prostate Cancer Foundation (PCF) announced six new Challenge Awards to advance the treatment of lethal prostate cancer. PCF Challenge Awards are multi-year awards supporting cross-disciplinary teams of research scientists. $39 million went toward supporting research programs in 2014. [Prostate Cancer Foundation]
    Press Release

    OncoGenex Announces Update on Phase III AFFINITY Trial Evaluating Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer
    OncoGenex Pharmaceuticals, Inc. announced that the AFFINITY trial is continuing as planned based upon completion of the interim futility analysis and the recommendation of the Independent Data Monitoring Committee. [OncoGenex Pharmaceuticals, Inc.] Press Release

    New wallchart from our sponsor:
    Mesenchymal Stem Cells (a Nature Reviews Molecular Cell Biology collaboration).
    Request your free copy.

     
    POLICY NEWS
    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

     
    EVENTS
    NEW CIRM 2.0 Free Webinar – Changing the Way We Work
    January 21, 2015, 12:00 PM PST
    Online

    NEW 2nd International Congress on Stem Cell and Cellular Therapies (ICSCCT)
    October 15-18, 2015
    Antalya, Turkey

    Visit our events page to see a complete list of events in the prostate cell community.

     
    JOB OPPORTUNITIES
    NEW Director (California Institute for Regenerative Medicine)

    Postdoctoral Research Fellow – Post-Transcriptional Gene Regulation Governing Cancer Cell Behavior (Fred Hutchinson Cancer Research Center)

    Postdoctoral Fellow – Wnt Signaling in Development and Disease (Van Andel Research Institute)

    Postdoctoral Fellow – Prostate Cancer Epigenetics and Genomics (UT Southwestern)

    PhD Studentship – Chemokine Receptor in Prostate Cancer Metastasis (University of East Anglia)

    Postdoctoral Position – Prostate Cell Biology (CEA/Grenoble )

    Postdoctoral Research Associate Positions – Cancer Biology (Hollings Cancer Center)

    Postdoctoral Position – Molecular Mechanisms and Translational Investigations of Advanced Prostate Cancer (Cleveland Clinic)

    Postdoctoral Researcher – Chromatin and Epigenetic Regulation (Van Andel Research Institute)

    Research Technologist – Media Development (STEMCELL Technologies Inc.)

    Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

    Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

    Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)


    Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

     

    Have we missed an important article or publication in Prostate Cell News? Click here to submit!

    Comments or suggestions? Submit your feedback here

    Learn more about Prostate Cell News: Archives | Events | Contact Us